14 March 2017 - Patients with atopic dermatitis are to get early access to Sanofi’s dupilumab before its marketing authorisation in the UK, after the Medicines and Healthcare Products Regulatory Agency issued a positive scientific opinion for the drug through the country’s Early Access to Medicines Scheme.

The Early Access to Medicines Scheme was established to secure early availability of innovative new unlicensed medicines to UK patients that have a high degree of unmet clinical need, and has to date largely focused on life-limiting conditions such as cancer. The inclusion of a treatment for atopic dermatitis, a type of chronic eczema, recognises how debilitating this condition can be and how much impact it can have on people’s physical and psychological wellbeing, said Sanofi.

Read Pharma Times article